ATE261721T1 - System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung - Google Patents

System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Info

Publication number
ATE261721T1
ATE261721T1 AT97927181T AT97927181T ATE261721T1 AT E261721 T1 ATE261721 T1 AT E261721T1 AT 97927181 T AT97927181 T AT 97927181T AT 97927181 T AT97927181 T AT 97927181T AT E261721 T1 ATE261721 T1 AT E261721T1
Authority
AT
Austria
Prior art keywords
drug
nanoparticles
specific target
mammalian body
stabilizers
Prior art date
Application number
AT97927181T
Other languages
English (en)
Inventor
Bernhard A Sabel
Ulrike Schroeder
Original Assignee
Nanopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanopharm Ag filed Critical Nanopharm Ag
Application granted granted Critical
Publication of ATE261721T1 publication Critical patent/ATE261721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
AT97927181T 1997-06-13 1997-06-13 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung ATE261721T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/003099 WO1998056361A1 (en) 1997-06-13 1997-06-13 Drug targeting system, method of its preparation and its use

Publications (1)

Publication Number Publication Date
ATE261721T1 true ATE261721T1 (de) 2004-04-15

Family

ID=8166655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927181T ATE261721T1 (de) 1997-06-13 1997-06-13 System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung

Country Status (9)

Country Link
US (1) US7025991B2 (de)
EP (1) EP0986373B1 (de)
JP (1) JP3778575B2 (de)
AT (1) ATE261721T1 (de)
AU (1) AU3176097A (de)
CA (1) CA2295177C (de)
DE (1) DE69728179T2 (de)
ES (1) ES2218685T3 (de)
WO (1) WO1998056361A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728179T2 (de) 1997-06-13 2004-11-25 Nanodel Technologies Gmbh System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US7651875B2 (en) * 1998-06-08 2010-01-26 Borealis Technical Limited Catalysts
EP1100475A1 (de) * 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Verwendung von arzneistoffbeladenen nanopartikel zur behandlung von krebs
AU5218500A (en) * 1999-06-22 2001-01-09 Aventis Research & Technologies Gmbh & Co. Kg Stable, radioactively marked nanoparticles, method for the production and utilization thereof
WO2001091808A2 (en) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
EP1495121A2 (de) * 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Mitteln und verfahren zur spezifischen hemmung von genen in zellen und gewebe vom zns und/oder dem auge
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
DK1526840T3 (da) * 2002-07-29 2008-11-03 Nanodel Technologies Gmbh Nanopartikler til DNA administration til et målorgan
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US20050053668A1 (en) * 2003-08-21 2005-03-10 Southwest Research Institute Skeletally targeted nanoparticles
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006029845A2 (en) * 2004-09-14 2006-03-23 Nanodel Technologies Gmbh Delivery vehicle containing nanoparticles
EP1661559A1 (de) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Verabreichungssystem hergestellt durch ein Miniemulsionsverfahren
WO2006056362A2 (en) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Delivery vehicle manufactured by the miniemulsion method
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20090304599A1 (en) * 2005-12-20 2009-12-10 Fujifilm Corporation Protein Nanoparticles and the Use of the Same
EP1815851A1 (de) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanopartikel zur Arzneistoffverabreichung
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP5201763B2 (ja) * 2007-02-28 2013-06-05 昇一 城武 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EA201001568A1 (ru) * 2008-05-06 2011-10-31 Глаксо Груп Лимитед Инкапсуляция биологически активных агентов
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
US10105317B2 (en) * 2009-07-07 2018-10-23 Anpac Bio-Medical Science Co., Ltd. Method of drug delivery
US8828246B2 (en) * 2010-02-18 2014-09-09 Anpac Bio-Medical Science Co., Ltd. Method of fabricating micro-devices
PL2560624T3 (pl) * 2010-04-23 2019-01-31 Kempharm, Inc. Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
US10967039B2 (en) 2013-05-28 2021-04-06 Sintef Tto As Process for preparing stealth nanoparticles
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
KR20190097729A (ko) * 2018-02-13 2019-08-21 서강대학교산학협력단 안질환 치료용 약물 전달 임플란트 및 이의 제조방법
BR112021003121A2 (pt) 2018-08-23 2021-05-11 Sintef Tto As nanopartículas
EP3952836A1 (de) 2019-04-10 2022-02-16 Sintef Tto As Nanopartikel mit copolymeren oder homopolymeren verbindungen, die cyanoacrylatuntereinheiten enthalten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2612400A1 (fr) 1987-03-16 1988-09-23 Centre Nat Rech Scient Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
WO1994015590A1 (en) * 1993-01-11 1994-07-21 Abacol Limited Small diameter nanocapsules, process for their preparation and applications thereof
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
ES2188652T3 (es) 1994-02-28 2003-07-01 Nanopharm Ag Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
DE69728179T2 (de) 1997-06-13 2004-11-25 Nanodel Technologies Gmbh System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
EP1100475A1 (de) 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Verwendung von arzneistoffbeladenen nanopartikel zur behandlung von krebs

Also Published As

Publication number Publication date
JP3778575B2 (ja) 2006-05-24
JP2001502721A (ja) 2001-02-27
EP0986373B1 (de) 2004-03-17
US7025991B2 (en) 2006-04-11
EP0986373A1 (de) 2000-03-22
DE69728179D1 (de) 2004-04-22
AU3176097A (en) 1998-12-30
DE69728179T2 (de) 2004-11-25
CA2295177C (en) 2007-01-09
US20020034474A1 (en) 2002-03-21
ES2218685T3 (es) 2004-11-16
CA2295177A1 (en) 1998-12-17
WO1998056361A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE261721T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
DE69926504T2 (de) Zubereitungen zur kontrollierten freisetzung mit mehrschichtstruktur
JPS63203629A (ja) コルチコステロイド類と組み合わせたジラーゼ阻害剤の局所的適用可能な配合物
CY1117668T1 (el) Φαρμακευτικες συστασεις περιλαμβανουσες ινσουλινη συμπλοκοποιημενη με μια δικετοπιπεραζινη
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP1570823A3 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
CN107714645A (zh) 纳米颗粒组合物
HUP0100155A2 (hu) Szubmikronos méretű 9-hidroxiriszperidon-zsírsav-észtereket tartalmazó vizes szuszpenziók
HUT74807A (en) Platelet growth accelerator
JPH0623112B2 (ja) コラ−ゲン性医薬組成物
JP2002532432A5 (de)
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE50206912D1 (de) Verfahren zur kontinuierlichen herstellung und beschichtung von selbstklebemassen auf basis von sbc mit mindestens einem pharmazeutischen wirkstoff
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
US4876086A (en) Injectable compositions of amoxycillin trihydrate
JP2002535293A (ja) 無針の経皮的粉末薬物送達を増強する方法
WO2007042833A3 (en) Arnphiphilic nanotubes and micelles comprising same for use in the delivery of biologically active agents
US20060165611A1 (en) Composition for Treating and Preventing Periodontal Disease and Method of Use
RU2141819C1 (ru) Мазь с интерфероном человеческим лейкоцитарным "интерон"
Kano et al. Dermal patch anaesthesia for venous cannulation with 10% lignocaine gel containing glycyrrhetinic acid monohemiphthalate disodium as an absorption promoter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties